• New Platform Speeds Development of Cell and Gene Therapies
    Operator manufacturing viral vector in a cGMP environment. Merck’s new VirusExpress™ Platform increases dose yields and reduces process development time for cell and gene therapies.

Laboratory Products

New Platform Speeds Development of Cell and Gene Therapies

Oct 13 2020

Merck has bolstered its viral vector manufacturing capabilities with the launch of its VirusExpress™ Lentiviral Production Platform. This new platform helps to overcome lentiviral production challenges and can reduce process development time by approximately 40%, based on Merck’s experience as a contract development and manufacturing organisation. 

 

“Cell and gene therapies offer the potential for curative treatments and are being developed and commercialised in half the time it has taken traditional therapies,” said Angela Myers, head of Gene Editing & Novel Modalities, Life Science, at Merck. “We are committed to accelerating manufacturing of cell and gene therapies with the ultimate goal of getting these lifesaving treatments to patients faster. By increasing dose yields and dramatically reducing process development time, this new platform will help us reach this goal.”

 

Using a suspension cell line rather than an adherent-based production, coupled with a chemically defined cell culture media and process with built-in scalability, Merck’s VirusExpress™ Platform meets multiple market needs. In addition to accelerating process development, the suspension culture format allows each batch of virus to be larger yielding more patient doses. Additionally, suspension culture is amenable to true scale-up, while being less labour-intensive. The chemically defined medium eliminates the safety, regulatory and supply chain concerns related to animal- and human-derived materials.

 

Merck’s VirusExpress™ Platform offers a simplified upstream workflow, making processes easier to manage, adjust and scale. Flexible licensing allows companies to manufacture vectors by using either Merck’s contract manufacturing capabilities, a third-party contract development and manufacturing organisation, or in-house development. 

More information online


Digital Edition

International Labmate July 2021

July 2021

In This Edition Articles - Deep characterisation and quantitative analysis - Seamless HPLC Method Transfer - How does a sample’s adventure unfold at Diamond? Mass Spectrometry & Spectr...

View all digital editions

Events

InformEx Zone at CPhl North America

Aug 10 2021 Pennsylvania, PA, USA & Online

Miconex

Aug 18 2021 Beijing, China

DioXin 2021

Aug 22 2021 Xi'an, China

ACS National Meeting & Expo, Fall 2021

Aug 22 2021 Atlanta, GA, USA & Virtual

Microscopy Conference 2021

Aug 22 2021 Digital event

View all events